| n | 144 | |||
| Gender (M:F) | 62:82 | |||
| Age (years) | 58.52 | ± | 12.65 | |
| Duration of diabetes (years) | 11.74 | ± | 6.07 | |
| Hight (cm) | 162.30 | ± | 9.11 | |
| Weight (kg) | 68.89 | ± | 12.92 | |
| BMI (kg/m2) | 26.11 | ± | 4.11 | |
| HbA1c (NGSP) (%) | 8.20 | ± | 0.68 | |
| SBP (mmHg) | 126.46 | ± | 12.27 | |
| DBP (mmHg) | 74.94 | ± | 11.62 | |
| Concomitant drugs used before the metformin dose increase. (n) | SU | 31 | ||
| SU + DPP-4 inhibitor | 16 | |||
| SU + insulin | 11 | |||
| SU + α-GI | 8 | |||
| SU + GLP-1 receptor agonist | 1 | |||
| SU + TZ | 1 | |||
| SU + insulin + α-GI | 1 | |||
| Insulin | 28 | |||
| Insulin +DPP-4 inhibitor | 1 | |||
| Insulin + α-GI | 1 | |||
| Insulin + TZ | 1 | |||
| DPP-4 inhibitor | 10 | |||
| DPP-4 inhibitor + α-GI | 1 | |||
| Glinide | 2 | |||
| Glinide + α-GI | 1 | |||
| α-GI | 2 | |||
| TZ | 2 | |||
| None | 26 | |||
| Complications | Hypertension | 30 | ||
| Hypertension + dyslipidemia | 37 | |||
| Hypertension + angine pectosis | 1 | |||
| Hypertension + dyslipidemia + ASO | 1 | |||
| Hypertension + dyslipidemia + Af | 1 | |||
| dyslipidemia | 21 | |||
| OMI | 3 | |||
| Angine pectosis | 2 | |||
| Af | 1 | |||
| ASO | 1 | |||
| Bronchial asthma | 1 | |||
| Hyperuricemia | 1 | |||
| None | 44 | |||